Why the study?
Does early initiation of apixaban compromise patient safety in patients with atrial fibrillation following TIA or small- to medium-sized acute ischemic stroke?
Does early initiation of apixaban compromise patient safety in patients with atrial fibrillation following TIA or small- to medium-sized acute ischemic stroke?
Early initiation of apixaban after TIA or small-to-medium acute ischemic stroke in patients with atrial fibrillation appears safe, though efficacy requires larger trials.
Answers are grounded in this paper and cite their sources.
Supports safety of early apixaban post-TIA or small/medium AIS in AF; leaves open efficacy confirmation in randomized trials.
Early initiation of anticoagulation after TIA, small-, or medium-sized AIS from AF does not appear to compromise patient safety. Potential efficacy of early initiation of anticoagulation remains to be determined from larger pivotal trials. Registration: URL: https://www.clinicaltrials.gov/; Unique identifier: NCT02283294.
No takes yet. Share an insight, caveat, or question.
Labovitz et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: